10 Jul Patricia Caetano
Bio
Dr. Caetano is currently the Executive Director of the Provincial Drug Programs at Manitoba Health, Healthy Living and Seniors (MHHLS). Additionally, Dr. Caetano maintains a part-time appointment through the University of Manitoba, Faculty of Medicine, Department of Community Health Sciences. Through her position with MHHLS, Dr. Caetano leads the development, implementation and evaluation of policies and programs that support a high quality and responsive provincial drug program. Dr. Caetano’s research training and expertise is specifically in the area of utilizing administrative health databases for measuring the population effectiveness of prescription therapies as well as the effects of policy changes on population-based drug utilization rates.
Dr. Caetano has been the co-principal investigator for the Manitoba site of the Canadian Network for Observational Drug Effect Studies (DSEN-CNODES) since its inception. She has contributed to the development and analysis of several CNODES studies and is a member of the Data Base and Knowledge Translation Teams. Her role as a provincial drug plan manager provides critical insight and value to the CNODES Steering Committee, leading to greater uptake of research results by government policy and decision-makers.
Dr. Caetano has authored/co-authored 27 peer-reviewed papers, 13 published abstracts, as well as a number of reports and media presentations. She holds a Doctor of Philosophy with specialty in Health Services Research and Pharmacoepidemiology (University of Manitoba) and was a Post-Doctoral fellow (2005-2006) at the Centre for Health Services and Policy Research, University of British Columbia, with a focus on pharmaceutical policy.
CNODES Projects
Changes in the dispensing of opioid medications in Canada following the introduction of a tamper-deterrent formulation of long-acting oxycodone: a time series analysis
Site Investigator, ManitobaThe use of atypical antipsychotics and the risk of breast cancer
Co-Site Investigator, ManitobaThe use of atypical antipsychotics and the risk of breast cancer
Co-Site Investigator, ManitobaUse of proton pump inhibitors and development of acute myocardial infarction
Co-Site Investigator, ManitobaProton pump inhibitors and the risk of Clostridium difficile infection
Co-Site Investigator, Manitoba